Immuron 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Steve Lydeamore

최고 경영자

AU$599.1k

총 보상

CEO 급여 비율	72.7%
CEO 임기	2.4yrs
CEO 소유권	n/a
경영진 평균 재임 기간	5.9yrs
이사회 평균 재임 기간	5.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Steve Lydeamore 의 보수는 Immuron 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$599k	AU$436k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$4m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$584k	AU$415k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	n/a	n/a	-AU$3m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$781k	AU$6k	-AU$3m

보상 대 시장: Steve 의 총 보상 ($USD 389.35K )은 Australian 시장( $USD 297.98K ).

보상과 수익: 회사가 수익성이 없는 동안 Steve 의 보상이 증가했습니다.

CEO

Steve Lydeamore (56 yo)

2.4yrs

테뉴어

AU$599,135

보상

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as Chief Executive Officer at Immuron Limited since June 27, 2022. He served as the Chief Executive Officer of Anatara Lifesciences Limite...

리더십 팀

이름	위치	테뉴어	보상	소유권
Steven Lydeamore	Chief Executive Officer	2.4yrs	AU$599.14k	데이터 없음
Jerry Kanellos	Chief Operating Officer	9.3yrs	AU$359.25k	0.15% A$ 25.0k
Flavio Palumbo	Chief Commercial Officer	2yrs	AU$347.61k	데이터 없음
Phillip Hains	CFO & Company Secretary	11.6yrs	데이터 없음	0.36% A$ 61.3k
David Lyon	Head of Marketing	no data	데이터 없음	데이터 없음

5.9yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 관리: IMC 의 관리팀은 노련하고 경험 (평균 재직 기간 5.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Glenn Tillotson	Member of Advisory Board	no data	데이터 없음	데이터 없음
Jeannette Joughin	Independent Non-Executive Director	less than a year	AU$7.55k	0% A$ 0
Daniel Pollock	Independent Non-Executive Director	12.1yrs	AU$127.65k	0.36% A$ 61.4k
Paul Brennan	Independent Non-Executive Chairman	2.7yrs	AU$153.60k	0% A$ 0
Dena Lyras	Member of Advisory Board	no data	데이터 없음	데이터 없음
Ravi Savarirayan	Independent Non-Executive Director	7.6yrs	AU$75.00k	0.38% A$ 65.8k
Sahil Khanna	Member of Advisory Board	no data	데이터 없음	데이터 없음
Paul Feuerstadt	Member of Advisory Board	no data	데이터 없음	데이터 없음
Teena Chopra	Member of Advisory Board	no data	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: IMC 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

Immuron 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited, Annual General Meeting, Nov 21, 2023

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

New major risk - Share price stability

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Insufficient new directors

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.87

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령